Navigation Links
ViroDefense Inc Announces Selection of Poliovirus Antiviral Preclinical Candidate
Date:6/3/2008

Compound Emerged from Technology Licensed from Schering-Plough Research

Institute

ROCKVILLE, Md., June 3 /PRNewswire-FirstCall/ -- ViroDefense Inc today announced that it has chosen to advance a compound licensed to ViroDefense Inc by Schering-Plough Corporation into IND-enabling preclinical studies for the prevention and treatment of poliovirus infections.

Schering-Plough licensed to ViroDefense Inc the exclusive rights for development of a specific compound series for polio indications. The license was provided in exchange for the purchase of compound testing supplies and potential future royalties on sales. Schering-Plough Research Institute had been developing the series for treatment of diseases caused by non-polio enteroviruses, such as the coxsackie viruses. ViroDefense Inc determined in laboratory tests that compounds of the series had promising anti-poliovirus activity.

The licensed compounds belong to the antiviral mechanistic class termed "capsid inhibitors." Compounds of this class inhibit the function of the poliovirus capsid, the outer protein coat of the virus, by integrating into the capsid at a specific site or pocket. By doing so, they prevent virus "uncoating" and the release of the viral RNA from the capsid, thereby blocking the initiation of the viral infection cycle.

The lead anti-poliovirus compound, V-073, has been shown to have potent and broad-spectrum anti-poliovirus specific activity, favorable pharmacologic and pharmacokinetic attributes, and the safety and tolerability profile suitable for its advancement as a preclinical candidate. Consequently, IND- enabling studies will commence with V-073.

"We are grateful to Schering-Plough for their willingness to offer this promising antiviral series for the fight against polio," commented Marc S. Collett, President of ViroDefense Inc. "This is clearly a humanitarian gesture on their part."

"We are very pleased to s
'/>"/>

SOURCE ViroDefense Inc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. BioElectronics Announces Profitability Breakeven and Additional Clinical Trials
2. Anesiva Announces South Korea FDA Approval of Adlea(TM) Investigational New Drug Application
3. Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytrens Contracture
4. Trubion Announces Presentation of Positive TRU-016 Data at ASCO
5. Alliance Pharmaceutical Corp. Announces Approval of Proposed Actions at Annual Shareholders Meeting
6. Vion Pharmaceuticals Announces Presentation of Interim Data from Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting
7. Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients at 44th ASCO Annual Meeting
8. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
9. IDM Pharma Announces Phase 2 Follow-Up Data Showing IDM-2101 is Well Tolerated With Positive Survival Trend in Non-Small Cell Lung Cancer Patients
10. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
11. CuraGen Announces Data From Ongoing Phase I/II Trial Showing Clinical Activity of CR011-vcMMAE in Metastatic Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Quebec , Jan. 15, 2014  Valeant Pharmaceuticals International, ... announced that the applicable waiting period under the Hart-Scott-Rodino ... the previously announced tender offer by its indirect wholly-owned ... outstanding shares of common stock of Solta Medical, Inc. ...
(Date:1/15/2014)... 2014  A novel wearable injector slightly larger than an Oreo ... to self-inject prescription drugs in the large doses required to ... autoimmune deficiencies, and genetic disorders.  An emerging ... 2018, according to analysts.   Many of these drugs will require ...
(Date:1/14/2014)... The Brandeis Medical Center, led by Dr. Emmanuel Brandeis , ... laser tattoo removal experience with the advanced Astanza Duality laser and ... quality cosmetic services with cutting edge medical technology and offering expert ... has seen a dramatic increase in the presence of ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2
... 2011 A new report in the March issue of ... beat brand names when it comes to safety, efficacy, and ... drug programs offering these drugs at prices as low as ... Walgreens, and Walmart have been steadily expanding their discount programs, ...
... JumpStart Ventures , the non-profit that invests in ... Ohio, and Cleveland Clinic , announced a ... Inc. The Cleveland-based company is developing a topical ... formation in wounds. (Logo: http://photos.prnewswire.com/prnh/20060209/CLJUMPSTARTLOGO) ...
Cached Medicine Technology:Consumer Reports Health: Best Drugs for What Ails You, Plus Where to Buy Them for $4 a Month 2Consumer Reports Health: Best Drugs for What Ails You, Plus Where to Buy Them for $4 a Month 3Consumer Reports Health: Best Drugs for What Ails You, Plus Where to Buy Them for $4 a Month 4JumpStart Ventures and Cleveland Clinic Invest in SironRX Therapeutics 2JumpStart Ventures and Cleveland Clinic Invest in SironRX Therapeutics 3JumpStart Ventures and Cleveland Clinic Invest in SironRX Therapeutics 4
(Date:7/9/2014)... from Montefiore Medical Center and the ... will present new findings at the Alzheimer,s Association International ... in Copenhagen, Denmark. Data from the four abstracts will ... normality to mild cognitive impairment and dementia. The research ... established in 1980 to examine healthy brain aging as ...
(Date:7/9/2014)... a reputation for being highly toxic, but when used in ... found to offer potential health benefits in a range of ... new compound (AP39), designed and made at the University of ... delivery of very small amounts of the substance to the ... Exeter have already found that the compound protects mitochondria ...
(Date:7/9/2014)... (July 9, 2014) A retrospective study conducted by ... colleagues reports that among adults with intellectual and developmental ... number of years receiving dental care increased. The findings, ... in Dentistry , may help improve interventions designed to ... , The researchers reviewed the dental records of ...
(Date:7/9/2014)... , , , , , ... , , , , ... SA80 assault rifle and the microphone is 50m downrange from the firer and approximately 30cm from the bullet... , ... , , , , , ... , , , , , ...
(Date:7/9/2014)... Medicine of the University of Southern California (USC) ... of the immune system are completely resistant to ... discovery suggests that blocking this immune system component ... hyper-inflammatory diseases such as rheumatoid arthritis and Type ... on June 23 in The Journal of ...
Breaking Medicine News(10 mins):Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 2Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 3Health News:Rotten egg gas holds key to healthcare therapies 2Health News:Adults with special needs see gains, challenges with long term oral care 2Health News:Adults with special needs see gains, challenges with long term oral care 3Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 2Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 3Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 4Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 5Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 6Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 7
... danger rises if the drugs are used with certain ... -- Antidepressant drugs called selective serotonin reuptake inhibitors (SSRIs), ... the risk of gastrointestinal bleeding, and the threat is ... and similar pain medications at the same time as ...
... Nurses Gain Stronger Voice for Patient Care, AUGUSTA, ... Center in Bangor, Maine appears to be over -- ... Registered nurses and hospital officials Thursday night reached ... the nurses say will,substantially enhance their voice in patient ...
... TO COMMENT ON THE MARKET FORECAST FOR THE DRUG, ... Ph.D., analyst,at Decision Resources, is available to discuss the ... of Merck,s Isentress, the,first integrase inhibitor drug which blocks ... new cells. Integrase inhibitors are a novel class ...
... New products, a growing world,population expected to reach ... the,aging of that population, will push anesthesia drug ... to Anesthesia Drugs: Worldwide Markets, a,new report by ... procedures required anesthetic,administration worldwide in 2006, and Kalorama ...
... Stryker Corporation,(NYSE: SYK ) disclosed today ... made an informal inquiry of the Company regarding ... connection with the sale,of medical devices in certain ... Securities and Exchange Commission regarding this,informal investigation. ...
... the 118 patients with portal vein thrombosis, noncirrhotic and ... with well tolerated bleed. Cirrhosis and tumor related portal ... Hypercoagulable state as a cause of portal vein thrombosis ... largest number of patients. , A research article to ...
Cached Medicine News:Health News:Antidepressants Boost GI Bleeding Risk 2Health News:MSNA: Strike Averted - Tentative Pact at EMMC 2Health News:Impending FDA Approval Decision on the First HIV Integrase Inhibitor Can Have Significant Impact for Patients 2Health News:Anesthesia Drugs Market to Grow to $4.3 Billion by 2011 as Populations and Uses for Anesthesia Increase 2Health News:Portal vein thrombosis is common in extraportal vein obstruction 2
... throughput reading of entire racks. Its scanner-based image ... and reads in approximately 10 seconds per rack. ... and a list of ActiveX controls is provided ... includes a USB HP Scanner and software. Compatible ...
... with powder-coated steel legs. Height ... in hundreds of sizes and ... light fixtures and ionizing equipment. ... custom building to meet special ...
Round, height-adjustable, steel laboratory stools with small footprint for small spaces • Choose options like different height-adjustment mechanism or paint finish. • your choice of color...
... This BioSafe room is configured specifically ... and chemical analysis. Panels are precision-joined ... easy to wipe down and disinfect. ... double-wall panel design creates strong, rigid ...
Medicine Products: